- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01190189
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Quebec, Kanada, G1S 2L6
- GSK Investigational Site
-
-
Alberta
-
Edmonton, Alberta, Kanada, T5A 4L8
- GSK Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3N1
- GSK Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- GSK Investigational Site
-
Truro, Nova Scotia, Kanada, B2N 1L2
- GSK Investigational Site
-
-
Ontario
-
Waterloo, Ontario, Kanada, N2L 6H6
- GSK Investigational Site
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1H 1Z1
- GSK Investigational Site
-
-
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- GSK Investigational Site
-
Golden, Colorado, Vereinigte Staaten, 80401
- GSK Investigational Site
-
-
Florida
-
Coral Gables, Florida, Vereinigte Staaten, 33134
- GSK Investigational Site
-
Miami, Florida, Vereinigte Staaten, 33136
- GSK Investigational Site
-
-
Georgia
-
Augusta, Georgia, Vereinigte Staaten, 30912
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- GSK Investigational Site
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, Vereinigte Staaten, 40004
- GSK Investigational Site
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68131
- GSK Investigational Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- GSK Investigational Site
-
-
North Carolina
-
New Bern, North Carolina, Vereinigte Staaten, 28562
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44122
- GSK Investigational Site
-
-
Pennsylvania
-
Carnegie, Pennsylvania, Vereinigte Staaten, 15106
- GSK Investigational Site
-
Erie, Pennsylvania, Vereinigte Staaten, 16508
- GSK Investigational Site
-
Erie, Pennsylvania, Vereinigte Staaten, 16507
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15236
- GSK Investigational Site
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- GSK Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84109
- GSK Investigational Site
-
Salt Lake City, Utah, Vereinigte Staaten, 84121
- GSK Investigational Site
-
-
Washington
-
Wenatchee, Washington, Vereinigte Staaten, 98801
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subjects who the investigator believes can and will comply with the requirements of the protocol
- A subject previously enrolled in study NCT00294047, who received the control vaccine, and who cannot receive the GSK580299 vaccine because the subject is above the age for which the vaccine is licensed.
- Written informed consent obtained from the subject
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Pregnant or breastfeeding.
- A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose.
- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Previous vaccination against HPV or planned administration of another HPV vaccine during the study other than that foreseen in the protocol.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone greater than or equal to 20 mg/day, or equivalent. Inhaled and topical steroids are allowed
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days (i.e., Day 0-29) of each dose of vaccine, with the exception of administration of routine meningococcal, hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccine up to 8 days before each dose of study vaccine. Enrolment will be deferred until the subject is outside of specified window.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
NOTE: Subjects enrolled in this study may also be eligible for a four-year gynaecological follow-up of the HPV-015 study, in which no investigational product will be administered. Subjects will be invited to the gynaecological follow-up study if either of the following applies:
- if they test positive for oncogenic HPV infection, but display normal cervical cytology at their concluding HPV-015 study end visit;
if they are pregnant so that no cervical sample can be taken at their concluding HPV-015 study end visit;
- Previous administration of any components of the vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Cancer or autoimmune disease under treatment.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
- History of any neurological disorders or seizures.
- Acute disease and/or fever at the time of enrolment.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Cervarix Group
Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
|
3-Dosen-Schema zur intramuskulären Impfung
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Subjects Reporting Any, Grade 3 and Related Serious Adverse Events (SAEs)
Zeitfenster: During the entire study period (from Day 0 up to Month 12)
|
Assessed SAEs included medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were congenital anomalies/birth defects in the offspring of a study subject.
Any SAE = occurrence of the SAE regardless of intensity grade.
Grade 3 SAE = an SAE which prevented normal, everyday activities.
Related SAE = an SAE assessed by the investigator as causally related to the study vaccination.
|
During the entire study period (from Day 0 up to Month 12)
|
Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)
Zeitfenster: During the entire study period (from Day 0 up to Month 12)
|
Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases, or (2) not related to routine visits for physical examination or vaccination, or as SAEs that were not related to common diseases.
Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.
Any MSC = occurrence of the MSC regardless of intensity grade.
Grade 3 MSC = a MSC which prevented normal, everyday activities.
Related MSC = MSC assessed by the investigator as related to the study vaccination.
|
During the entire study period (from Day 0 up to Month 12)
|
Number of Subjects Reporting Any, Grade 3 and Related Potentially Immune-Mediated Diseases (pIMDs)
Zeitfenster: During the entire study period (from Day 0 up to Month 12)
|
pIMD(s) are a subset of medically significant conditions (MSCs) that included autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have had an autoimmune aetiology.
Any pIMD = occurrence of the pIMD regardless of intensity grade.
Grade 3 pIMD = a pIMD which prevented normal, everyday activities.
Related pIMD = pIMD assessed by the investigator as related to the study vaccination.
|
During the entire study period (from Day 0 up to Month 12)
|
Number of Subjects Reporting Pregnancies and Outcomes of the Reported Pregnancies
Zeitfenster: During the entire study period (from Day 0 up to Month 12)
|
Pregnancy is the term used to describe the period in which a fetus develops inside a woman's womb or uterus.
In this study, the number of subjects with pregnancies was calculated.
The subjects with confirmed pregnancies were followed up to determine the outcomes of the reported pregnancies.
|
During the entire study period (from Day 0 up to Month 12)
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 113621
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Infektionen, Papillomavirus
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Kanazawa Medical UniversityMerck Sharp & Dohme LLCUnbekanntPapillomavirus-Infektionen | Papillomavirus-Impfstoffe
-
CHU de Quebec-Universite LavalCentre hospitalier de l'Université de Montréal (CHUM); Institut National en... und andere MitarbeiterAbgeschlossenHumane Papillomavirus-InfektionenKanada
-
Centre Hospitalier Universitaire de BesanconAbgeschlossenHumane Papillomavirus-InfektionFrankreich
-
University Hospital, GenevaAbgeschlossenHumane Papillomavirus-InfektionSchweiz
-
University of ConnecticutAbgeschlossenHumane Papillomavirus-Infektion
-
Indiana UniversityMerck Sharp & Dohme LLCUnbekanntHumane Papillomavirus-InfektionVereinigte Staaten
-
Gen-Probe, IncorporatedAbgeschlossenHumane Papillomavirus-InfektionVereinigte Staaten
-
GlaxoSmithKlineAbgeschlossen
Klinische Studien zur GSK580299 (Cervarix)
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusRussische Föderation, Singapur, Australien, Portugal
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusNiederlande, Schweden
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusVereinigte Staaten, Kanada
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusKanada, Vereinigte Staaten
-
GlaxoSmithKlineAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusChina
-
National Institute for Public Health and the Environment...BeendetHumane Papillomavirus-Infektion
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusBrasilien
-
GlaxoSmithKlineAbgeschlossenInfektionen, PapillomavirusHongkong
-
N.M. WulffraatNational Institute for Public Health and the Environment (RIVM)AbgeschlossenSystemischer Lupus erythematodes | Juvenile idiopathische Arthritis | Juvenile DermatomyositisNiederlande